OPINION

TOP STORIES

MEDICAL DEVICES

KEY THEMES

ARCHIVE & SEARCH

SIGN UP

LOG IN

COUNTRIES COVERED THIS EDITION

154 NEW stories in THIS EDITION
10,468 stories IN THE SITE since 2015

Forecasting & Launch Pricing Tool  

LIGHT - CONTENT AVAILABLE WITHOUT SUBSCRIPTION

 

KEY THEMES

 

About Akceso

Akceso Advisors A.G. offers professional support in the field of market patient access and pricing to the pharmaceutical industry. In the past decade, we had numerous success stories, delivering valuable market input for both leading pharmaceutical companies and SMEs worldwide. Our international team supports every client carrying out major-impact payer and pricing strategy projects, with the help of our state-of-the-art Verity Prices database and our cutting-edge international reference pricing tools.

CONTACT US:
Phone: +41 61 225 4393
Fax: +41 61 225 4391
Email: ask@akceso.ch
Website: https://akceso.ch/
Address: Akceso Advisors AG Aeschengraben 29. CH-4051 Basel Switzerland
Visit Our Website  

ABOUT THIS SITE

In our newsletter we provide a monthly view of developments in pricing, reimbursement, and market access across the globe. Since its launch in June 2015, we have covered more than 10,000 stories from over 150 countries. On this site, you can find all of the stories from the beginning and we update it monthly.

This is the Home page, here you can find the headlines of the recent news.

Already have an account?  Click on LOG IN button at the top of the page and enjoy the full functionality of the site! Read the full Opinion, the news extracts or use ARCHIVE & SEARCH page for all news in the past. 

Don't have an account yet?  Go to the "Light - Content available without subscription" section, you can read some selected news here. Use SIGN UP button at the top of the page to request access and use all features including opinion, archive and search.

Having any question, please contact us at primaheadlines@akceso.ch

Visit our website and read more about the features of our service!

READ MORE

OPINION

EUROPE FACES THE UNCERTAIN REALITY OF MFN: STICK OR TWIST?

When President Trump's Most Favoured Nation (MFN) drug pricing policy was signed by executive order in May 2025 there was huge speculation as to what the impact might be, but very little detail. By the end of 2025 the reality of the policy was starting to become apparent, with pharmaceutical companies forced to strike access/pricing deals on threat of tariffs and the announcement of three reference pricing frameworks (GENEROUS, GLOBE & GUARD).

Three months into 2026, evidence is emerging that is reshaping the European pharmaceutical landscape in three distinct ways: forcing launch delays and market withdrawals, threatening the confidentiality of European net pricing agreements, and diverting investment capital toward the United States. With 16 of 17 major pharmaceutical companies having signed MFN deals with the White House, the policy is no longer a future risk but an active commercial pressure on European health systems, patients, and payers.

Background: What Is MFN and How Does It Work?

MFN pricing links US drug prices to the lowest prices paid in a basket of comparable OECD countries. Because European markets pay far less ...

READ THE FULL ARTICLE

 

TOP STORIES

Forecasting & Launch Pricing Tool  

ASIA PACIFIC

 

EUROPE

 

LATIN AMERICA

 

MIDDLE EAST & AFRICA

 

NORTH AMERICA

 

MEDICAL DEVICES